tegaserod
Sign in to saveAlso known as HTF919, SDZ-HTF-919, 1-{[(5-Methoxyindol-3-yl)methylene]amino}-3-pentylguanidine, (E)-tegaserod
Tegaserod is a 5-HT4 agonist manufactured by Novartis and sold under the names Zelnorm and Zelmac for the management of irritable bowel syndrome and constipation. Approved by the FDA in 2002, it was subsequently removed from the market in 2007 due to FDA concerns about possible adverse cardiovascular effects. Before then, it was the only drug approved by the United States Food and Drug Administration to help relieve the abdominal discomfort, bloating, and constipation associated with irritable bowel syndrome. Its use was also approved to treat chronic idiopathic constipation.
Research
542 papers- Tegaserod for the Treatment of Irritable Bowel Syndrome.Anti-inflammatory & anti-allergy agents in medicinal chemistry · 2020
- Tegaserod: What's Old Is New Again.Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association · 2022
- Tegaserod.2006
- Tegaserod.Drugs · 1999
- Tegaserod for Irritable Bowel Syndrome With Constipation in Women Younger Than 65 Years Without Cardiovascular Disease: Pooled Analyses of 4 Controlled Trials.The American journal of gastroenterology · 2021
via PubMed
Wikidata facts
- Mass
- 301.190260356
Show 7 more facts
- defined daily dose
- 12
- chemical formula
- C₁₆H₂₃N₅O
- canonical SMILES
- CCCCCNC(=N)NN=CC1=CNC2=C1C=C(OC)C=C2
- World Health Organisation international non-proprietary name
- tegaserod
- NCI Thesaurus ID
- C66583
- Commons category
- Tegaserod
- isomeric SMILES
- CCCCCNC(=N)N/N=C/c1c[nH]c2ccc(OC)cc12
via Wikidata · CC0
~2 min read
Article
3 sectionsContents
- Mechanism of action
- Withdrawal from market
- References
Tegaserod is a 5-HT4 agonist manufactured by Novartis and sold under the names Zelnorm and Zelmac for the management of irritable bowel syndrome and constipation. Approved by the FDA in 2002, it was subsequently removed from the market in 2007 due to FDA concerns about possible adverse cardiovascular effects. Before then, it was the only drug approved by the United States Food and Drug Administration to help relieve the abdominal discomfort, bloating, and constipation associated with irritable bowel syndrome. Its use was also approved to treat chronic idiopathic constipation.
==Mechanism of action== The drug functions as a motility stimulant, achieving its desired therapeutic effects through activation of the 5-HT4 receptors of the enteric nervous system in the gastrointestinal tract. It also stimulates gastrointestinal motility and the peristaltic reflex, and allegedly reduces abdominal pain. Additionally, tegaserod is a 5-HT2B receptor antagonist.